Main Menu
— Faculty —

HUANG, Ziwei


Presidential Chair Professor

Education Background

Postdoc. in Biochemistry University of California, San Francisco, CA (1993-1995 )

Ph.D. in Chemistry University of California, San Diego, CA (1988-1993 )

B.S. in Chemistry South China Normal University, China (1982-1986)

Research Field
Pharmaceutical sciences; pharmacology; translational research; precision medicine


Professor Huang Ziwei graduated from the University of California, San Diego in 1993. From 1995 to 2000, he served as an assistant professor at the Kimmel Cancer Center at Jefferson University School of Medicine in Philadelphia, USA. From 2000 to 2004, he was a lifelong associate professor at the Department of Biochemistry and Chemistry at the University of Illinois at Urbana-Champaign (UIUC). From 2004 to 2009, he served as a professor at the Painan Medical Research Institute in San Diego, California. From 2009 to 2013, he served as a tenured professor in the Department of Pharmacology at the State University of New York. He was also the head of the department. Dean of the Cancer Institute, New York Center for New Drug Discovery and Development. Director, and Associate Vice President of University Research and International Cooperation.

Professor Huang Zi has published more than 100 research, review and conference papers in international academic journals and works, and has obtained a number of new biomedical discoveries for the treatment of human immune system diseases, cancer and AIDS.

Professor Huang Ziwei has been committed to the cultivation of academic talents for many years. Over 20 years of training and mentoring more than 100 postdocs, graduate students and technicians. Among them, more than 10 post-doctoral students from China have served as academicians, directors, professors, chief scientists, and national 863 project review experts in many universities and research institutes in China, and are active in the field of biomedical research in China.

Academic Publications:

1. Huang Z, He YB, Raynor K, Tallent M, Reisine T and Goodman M. Main chain and side chain chiral methylated somatostatin analogs: syntheses and conformational analyses. J. Am. Chem. Soc.114:9390-9401, 1992.
2. He YB, Huang Z, Raynor K, Reisine T and Goodman M. Syntheses and conformations of somatostatin related cyclic hexapeptides incorporating specific α- and β-mehtylated residues. J. Am. Chem. Soc. 115:8066-8072, 1993.
3. Huang Z, Probstl A, Spencer JR, Yamazaki T and Goodman M. Cyclic hexapeptide analogs of somatostatin containing bridge modifications: syntheses and conformational analyses. Int. J. Peptide Protein Res. 42:352-365, 1993.
4. Pan KM, Baldwin MA, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE and Prusiner SB. Conversion of α-Helices into β-Sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA 90:10962-10966, 1993.
5. Huang Z, Gabriel JM, Baldwin MA, Fletterick RJ, Prusiner SB and Cohen FE. Proposed threedimensional structure for the cellular prion protein. Proc. Natl. Acad. Sci. USA 91:7139-7143, 1994.
6. Baldwin MA, Pan KM, Nguyen J, Huang Z, Groth D, Serban A, Gasset, M, Mehlhorn I, Fletterick RJ, Cohen FE and Prusiner SB. Spectroscopic characterization of conformational differences between PrP-C and PrP-Sc: an α-Helix to β-Sheet transition. Phil. Trans. Roy. Soc. London B.
343:435-441, 1994.
7. Stone DB, Schneider DK, Huang Z and Mendelson RA. The radius of gyration of native andreductively methylated myosin subfragment-1 from neutron scattering. Biophy. J. 69: 767-776,1995.
8. Huang Z, Prusiner SB and Cohen FE. Scrapie prions: a three-dimensional model of an infectiousfragment. Folding & Design 1: 13-19, 1996.
9. Satoh T, Li S, Friedman TM, Wiaderkiewicz R, Korngold R and Huang Z. Synthetic peptidesderived from the fourth domain of CD4 antagonize CD4 function and inhibit T cell activation.Biochem. Biophys. Res. Commun. 224: 438-443, 1996.
10. Satoh T, Aramini JM, Li S, Friedman T, Gao J, Edling A, Townsend R, Germann MW, Korngold Rand Huang Z. Bioactive peptide design based on protein surface epitopes: a cyclic heptapeptideZiwei Huang, Ph.D. Curriculum Vitae15mimics CD4 domain 1 CC’ loop and inhibits CD4 biological function. J. Biol. Chem. 272: 12175-12180, 1997.
11. Li S, Gao J, Satoh T, Friedman T, Edling A, Koch U, Choksi S, Han X, Korngold R and Huang Z. A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics. Proc. Natl. Acad. Sci. USA 94: 73-78, 1997.
12. Resnicoff M, Huang Z, Herbert D, Blattler WA, Lutz RJ and Baserga R. A novel class of peptides that induce apoptosis and abrogate tumorigenesis in vivo. Biochem. Biophy. Res. Commun. 240: 208-212, 1997.
13. Butcher D, Kowalska MA, Li S, Luo Z, Shan S, Lu Z, Niewiarowski S and Huang Z. A natural motif approach to protein design: a synthetic leucine zipper peptide mimics the biological function of the platelet factor 4 protein. FEBS lett. 409: 183-187, 1997.
14. Luo Z, Butcher D and Huang Z. Molecular modeling of interleukin-8 receptor β and analysis of receptor-ligand interaction. Protein Eng. 10: 1039-1045, 1997.
15. Srinivasula SM, Ahmad M, MacFarlane M, Luo Z, Huang Z, Fernandes-Alnemri T and Alnemri ES. Generation of constitutively active recombinant caspase-3 and -6 by rearrangement of their subunits. J. Biol. Chem. 273: 10107-10111, 1998.
16. Luo Z, Butcher D, Murali R, Srinivasan A and Huang Z. Structural studies of synthetic peptide fragments derived from the HIV-1 vpr protein. Biochem. Biophy. Res. Commun. 244: 732-736, 1998.
17. Li S, Choksi S, Shan S, Hu X, Gao J, Korngold R and Huang Z. Identification of the CD8 DE loop as a surface functional epitope: implications for MHC class I binding and CD8 inhibitor design. J. Biol. Chem. 273: 16442-16445, 1998.
18. Li S, Satoh T, Korngold R and Huang Z. CD4 dimerization and oligomerization: implications for T-cell function and structure-based drug design. Immunology Today 19: 455-462, 1998.
19. Butcher DJ, Luo Z and Huang Z. The roles of side chain and backbone in protein structure probed with glycine- and sarcosine-rich synthetic leucine zipper peptides. Biochem. Biophy. Res. Commun., 265: 350-355, 1999.
20. Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, Raida M, Vijay-Kumar S, Huang Z, Lobb RR and Niewiarowski S. EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner. J. Biol. Chem. 274: 12468-12473, 1999.
21. Reiss K, Yumet G, Shan S, Huang Z, Alnemri E, Srinivasula SM, Wang J, Morrione A and Baserga R. A synthetic peptide sequence from the C-terminus of the insulin-like growth factor-I receptor that induces apoptosis and inhibition of tumor growth. J. Cell. Physiol. 181: 124-135, 1999.
22. Rubini M, D’Ambrosio C, Carturan S, Yumet G, Catalano E, Shan S, Huang Z, Criscuolo M, PifferiM and Baserga R. Characterization of an antibody that can detect an activated IGF-1 receptor in human cancers. Exp. Cell Res. 251: 22-32, 1999.
23. Luo J, Luo Z, Zhou N, Hall JW and Huang Z. Attachment of C-terminus of SDF-1 enhances the biological activity of its N-terminal peptide. Biochem. Biophy. Res. Commun. 264: 42-47, 1999.
24. Luo Z, Zhou N, Luo J, Hall JW and Huang Z. The role of positively charged residues in CXCR4 recognition probed with synthetic peptides. Biochem. Biophy. Res. Commun. 263: 691-695, 1999.
25. Zhou N, Luo Z, Hall JW, Luo J, Han X and Huang Z. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction. Euro. J. Immunol. 30: 164-173, 2000.
26. Sarmiento M, Wu L, Feng YF, Li S, Luo Z, Huang Z, Yuan AK and Zhang ZY. Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B. J. Med. Chem., 43: 146-155, 2000.
27. Zhou N, Luo Z, Luo J, Hall JW and Huang Z. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry, 39: 3782-3787, 2000.
28. Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R and Huang Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res., 60: 1498-1502, 2000.
29. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES and Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA, 97: 7124-7129, 2000.
30. Yu N, Aramini JM, Germann MW and Huang Z. Reactions of salicylaldehydes with alkyl cyanoacetates on the surface of solid catalysts: syntheses of 4H-chromene derivatives. Tetrahedron Letters, 41: 6993-6996, 2000.
31. Luo Z, Fan X, Zhou N, Hiraoka M, Luo J, Kaji H, and Huang Z. Structure-function study and anti-HIV activity of synthetic peptide analogs derived from viral chemokine vMIP-II. Biochemistry, 39: 13545-13550, 2000.
32. Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z and Alnemri ES. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J. Biol. Chem., 275: 36152-36157, 2000.
33. Edling AE, Choksi S, Huang Z and Korngold R. Effect of a cyclic heptapeptide based on the human CD4 domain 1 CC’-loop region on murine experimental allergic encephalomyelitis: inhibition of both primary and secondary responses. J. Neuroimmunol., 112: 115-28, 2001.
34. Zhou N, Luo Z, Luo J, Liu D, Hall JW, Pomerantz RJ and Huang Z. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J. Biol. Chem., 276: 42826-42833, 2001.
35. Edling AE, Choksi S, Huang Z and Korngold R. An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis. J. Autoimmunity, 18: 169- 179, 2002.
36. Milella M, Kornblau SM, Estrov Z, Konopleva M, Tari A, Schober WD, Carter B, Harris D, Leysath CL, Berestein GL, Sebolt-Leopold JS, Huang Z and Andreeff M. Simultaneous disruption of the Bcl-2 and MEK/MAPK pathways sinergistically induces apoptosis in acute myelogenous leukemia. Blood, 99: 3461-3464, 2002.
37. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN and Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res., 62: 466-471, 2002.
38. Zhou N, Luo Z, Luo J, Fan X, Cayabyab M, Hiraoka M, Liu D, Han X, Pesavento J, Dong C, Wang Y, An J, Kaji H, Sodroski JG and Huang Z. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J. Biol. Chem., 277: 17476-17485, 2002.
39. Khan MZ, Brandimarti R, Patel JP, Huynh N, Wang J, Huang Z, Fatatis A and Meucci O. Apoptotic and antiapoptotic effects of CXCR4: is it a matter of intrinsic efficacy? Implications for HIV neuropathogenesis. AIDS Res. Hum. Retroviruses, 2004, 20: 1063-71.
40. An J, Chen Y and Huang Z. Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor. J. Biol. Chem., 279:19133-40, 2004.
41. Yang B, Liu D and Huang Z. Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. Bioorg. Med. Chem. Lett.,14:1403-1406, 2004.
42. Tian S, Choi WT, Liu D, Pasavento J, Wang Y, An J, Sodroski JG and Huang Z. Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1α on CXCR4 transmembrane helical domains. Journal of Virology, 2005, 79: 12667-12673.
43. Mori, M, Liu, D, Kumar S and Huang Z. NMR structures of anti-HIV D-peptides derived from the N-terminus of viral chemokine vMIP-II. Biochem. Biophy. Res. Commun., 2005, 335: 651-658.
44. Liu D, Yang B, Cao R and Huang Z. A chemical strategy to promote helical peptide-protein interactions involved in apoptosis. Bioorg. Med. Chem. Lett. 2005, 15: 4467-9.
45. Dong, CZ, Kumar S, Choi WT, Madani N, Tian S, An J, Sodroski JG and Huang Z. Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand. J. Med. Chem., 2005, 48: 7923-2924.
46. Choi WT, Tian S, Dong CZ, Kumar S, Liu D, Madani N, An J, Sodroski JG and Huang Z. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors. Journal of Virology, 2005, 79: 15398- 15404.
47. Kumar S, Choi WT, Dong CZ, Madani N, Tian S, Liu D, Wang Y, Pesavento J, Wang J, Fan X, Yuan J, An J, Sodroski JG, Richman DD and Huang Z. SMM-Chemokines: a class of unnatural Synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. Chemistry & Biology, 2006, 13: 1-11.
48. Shiryaev S, Ratnikov BI, Chekanov AV, Sikora S, Rozanov DV, Wang J, Smith JW, Huang Z, Lindberg I, Samuel MA, Diamond MS and Strongin AY. Structural and functional analysis identifies the inhibitors and the cleavage targets of the West Nile virus NS3 processing proteinase.
Biochem J., 2006, 393: 503-511.
49. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M and Konopleva M. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol. Cancer Ther., 2006, 12: 3113-3121.
50. Nie A and Huang Z. Microwave-assisted reaction of 2′-hydroxychalcones with hydrazides to synthesize flavanone hydrazone and 4, 5-dihydropyrazole derivatives. J. Comb. Chem., 2006, 8: 655-8.
51. Nie A, Wang J and Huang Z. Microwave-assisted Solution Parallel Synthesis of 2,4,6-trisubstituted Pyrimidines. J. Comb. Chem., 2006, 8:646-8.
52. Wang J, Kumar S, Choi WT, Dong C and Huang Z. Design and synthesis of novel chemokine analogs derived from vMIP-II. Protein Pept Lett. 2006, 13: 499-501.
53. An J, Chervin AS, Nie A, Ducoff HS, and Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene, 2007, 26: 652-661.
54. Li Y, Guo Y, Kumar S, Liu D and Huang Z. Crystal structure of a chemically synthesized, anti-HIV chemokine vMIP-II. PROTEINS: Structure, Function, and Bioinformatics, 2007, 67: 243-6.
55. Choi WT, Kaul M, Kumar S, Wang J, Dong CZ, An J, Lipton SA and Huang Z. Neuronal apoptotic signaling pathways probed and intervened by synthetically and modularly modified (SMM) chemokines. J. Biol. Chem., 2007, 282:7154-63.
56. Liu D, Madani N, Li Y, Cao R, Choi WT, Kawatkar SP, Lim MY, Kumar S, Dong CZ, Russell JD, Lefebure CR, An J, Wilson S, Gao YG, Pallansch LA, Sodroski JG and Huang Z. Crystal structure and structural mechanism of a novel anti-human immunodeficiency virus and D-amino acidcontaining chemokine. J. Virology, 2007, 81:11489-11498.
57. Wang Y, Cao R, Liu D, Chervin A, Yuan J, An J and Huang Z. Oligomerization of BH4-truncated Bcl-x(L) in solution. Biochem. Biophys. Res. Commun., 2007, 361:1006-11. Ziwei Huang, Ph.D. Curriculum Vitae 19
58. Drag M, Mikolajczyk J, Krishnakumar IM, Huang Z and Salvesen GS. Activity profiling of human deSUMOylating enzymes (SENPs) with synthetic substrates suggests an unexpected specificity of two newly characterized members of the family. Biochem. J., 2008, 409:461-9.
59. Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC. Differential regulation of Bax and Bak by antiapoptotic Bcl-2-family proteins, Bcl-B and Mcl-1. J Biol Chem., 2008, 283: 9580–9586.
60. Wu D, Pang Y, Ke Y, Yu J, He Z, Tautz L, Mustelin T, Ding S, Huang Z and Feng GS. A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase. PLoS ONE, 2009, 4:e4914.
61. Crisostomo FR, Feng Y, Zhu X, Welsh K, An J, Reed JC and Huang Z. Design and synthesis of a simplified inhibitor for XIAP-BIR3 domain. Bioorg. Med. Chem. Lett., 2009, 19:6413-8.
62. Krieg A, Correa RG, Garrison JB, Negrate GL, Welsh K, Huang Z, Knoefel WT and Reed JC. XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl. Acad. Sci. USA, 2009, 106:14524-9.
63. Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z and Pasquale EB. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry, 2010, 49:6687-6695.
64. Hu Q, Nie A, Welsh K, Crisóstomo FR, Zhu X, Li Z, An J, Reed JC, Zhang L and Huang Z. Novel XIAP inhibitors as probes of apoptosis in biology and medicine. Exp. Biol. Med., 2011, 236:247-51.
65. Garrison JB, Correa RG, Gerlic M, Yip KW, Krieg A, Tamble CM, Shi R, Welsh K, Duggineni S, Huang Z, Ren K, Du C, Reed JC. ARTS and Siah collaborate in a pathway for XIAP degradation. Mol. Cell, 2011, 41:107-16.
66. Kawatkar SP, Yan M, Gevariya H, Lim MY, Eisold S, Zhu X, Huang Z and An J. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists. Exp. Biol. Med., 2011, 236:844-50.
67. Dong CZ, Tian S, Madani N, Kumar S, Choi WT, Liu D, Sodroski JG, Huang Z and An J. Role of CXCR4 internalization in the anti-HIV activity of SDF-1a probed by a novel synthetically and modularly modified-chemokine analog. Exp. Biol. Med., 2011, 236:1413-9.
68. Noberini R, Mitra S, Salvucci O, Valencia F, Duggineni S, Prigozhina N, Wei K, Tosato G, Huang Z and Pasquale EB. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity. PloS One, 2011, 6:e28611.
69. Tian W, Xu Y, Han X, Duggineni S, Han X, Huang Z and An J. Development of a novel fluorescence polarization-based assay for studying the β-catenin/Tcf4 interaction. J. Biomol. Screen., 2012, 4:530-4.
70. Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N, Luo G, Li YM, Han X, Huang Z and An J. Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction. Biochemistry, 2012, 51:724-31.
71. Mao Y, Lin N, Tian W, Han X, Han X, Huang Z and An J. Design, synthesis, and biological evaluation of new diaminoquinazolines as β-catenin/Tcf4 pathway inhibitors. J. Med. Chem., 2012, 55:1346-59.
72. Dong CZ, Tian S, Choi WT, Kumar S, Liu D, Xu Y, Han X, Huang Z and An J. Critical role in CXCR4 signaling of the polypeptide main chain in the amino-terminus of SDF-1a probed by novel N-methylated SMM-Chemokine Analogs. Biochemistry, 2012, 51:5951-7.
73. Choi WT, Kumar S, Madani N, Tian S, Dong CZ, Liu D, Yuan J, Sodroski JG, Huang Z and An J. A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry. Biochemistry, 2012, 51:7078-86.
74. Duggineni S, Mitra S, Noberini R, Han X, Lin N, Xu Y, Tian W, An J, Pasquale EB and Huang Z. Design, synthesis and characterization of novel small molecular inhibitors of Ephrin-B2 binding to EphB4. Biochem. Pharmacology, 2013, 85:507-13.
75. Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, Pasquale EB and Huang Z. Modulating Eph receptor signaling with synthetic bivalent ligands: Design and biological characterization of novel dimeric peptides targeting the EphA2 receptor. ACS Med. Chem. Letts., 2013, 4:344-348.
76. Xu Y, Duggineni S, Espitia S, Richman DD, An J, and Huang Z. A synthetic bivalent ligand of CXCR4 inhibits HIV infection. Biochem. Biophys. Res. Commun., 2013, 435:646-50.
77. Xi J, Zhu X, Feng Y, Luo G, Mao Y, Han X, Tian W, Wang G, Han H, Huang Z and An J. A novel class of tubulin inhibitors with promising anticancer activities. Mol. Cancer Res., 2013, 11:856-64.
78. Han X, Xu Y, Yang Y, Xi J, Tian W, Duggineni S, Huang Z and An J. Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity. PLoS One, 2013, 8(11):e80183.
79. Yang Y, Zhang Q, Gao M, Yang X, Huang Z and An J. A novel CXCR4-selective high-affinity fluorescent probe and its application in competitive binding assays. Biochemistry, 2014, 53(30):4881-3.
80. Yang Y, Gao M, Zhang Q, Yang X, Huang Z and An J. Design, synthesis and biological characterization of novel PEG-linked dimeric modulators for CXCR4. Bioorg. Med. Chem., 2016, 24(21):5393-5399.